Nashville, TN 的 小細胞肺癌 臨床試驗
20 項針對 小細胞肺癌 的研究正在 Nashville（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- Sarah Cannon Research Institute, Nashville
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
招募中1 期
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- Sarah Cannon Research Institute (SCRI), Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
招募中1/2 期
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
招募中3 期
- SCRI Oncology Partners /ID# 279779, Nashville
- Vanderbilt University Medical Center /ID# 280169, Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
招募中1 期
- Sarah Cannon - Tennessee Oncology, Nashville
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
招募中1/2 期
- SCRI Oncology Partners, Nashville
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
招募中3 期
- SCRI OP (Oncology Partners), Nashville
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
招募中3 期
- SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
招募中1/2 期
- Sarah Cannon Research Institute ( Site 7001), Nashville
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
招募中1/2 期
- SCRI Oncology Partners, Nashville
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
招募中1 期
- Sarah Cannon Research Institute (SCRI), Nashville
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
招募中2 期
- SCRI Oncology Partners, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
招募中1 期
- Tennessee Oncology, PLLC, Nashville
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
招募中1 期
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
招募中1/2 期
- Sarah Cannon Research Institute - Oncology Partners, Nashville
A Study of LY4175408 in Participants With Advanced Cancer
招募中1 期
- Sarah Cannon Research Institute, Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
招募中1/2 期
- Research Site 136, Nashville
其他城市的 小細胞肺癌 試驗
- Houston, TX26 項研究
- Arlington, VA23 項研究
- New York City, NY22 項研究
- Boston, MA21 項研究
- Los Angeles, CA20 項研究
- Orlando, FL15 項研究
- Dallas, TX13 項研究
- Cleveland, OH13 項研究
- Chicago, IL13 項研究
- St. Louis, MO13 項研究
- Detroit, MI12 項研究
- Washington, DC12 項研究
Nashville 的其他研究
- 非小細胞肺癌97 項研究
- 乳癌81 項研究
- 轉移性癌症70 項研究
- 大腸直腸癌69 項研究
- 癌症（所有類型）65 項研究
- 卵巢癌49 項研究
- 前列腺癌43 項研究
- 肺癌40 項研究
- 頭頸部鱗狀細胞癌39 項研究
- 胰臟癌39 項研究
- 子宮內膜癌38 項研究
- 黑色素瘤33 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。